Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance

被引:22
|
作者
Zink, Richard C. [1 ]
Huang Qin [2 ]
Zhang Lu-Yong [3 ]
Bao Wen-Jun [1 ]
机构
[1] SAS Inst Inc, Cary, NC USA
[2] SFDA, Ctr Drug Evaluat, Beijing 100053, Peoples R China
[3] China Pharmaceut Univ, Jiangsu Ctr Drug Screening, Nanjing 210009, Peoples R China
关键词
Disproportionality; Statistics; Graphics; Pharmacovigilance; Spontaneously-reported adverse events; SIGNAL GENERATION;
D O I
10.1016/S1875-5364(13)60035-7
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
AIM: Combine disproportionality analysis with dynamically interactive graphics to understand spontaneously-reported adverse events in pharmacovigilance. METHODS: Four statistical methods, including Reporting Odds Ratio, Proportional Reporting Ratio, Multi-Item Gamma Poisson Shrinker and Bayesian Confidence Propagation Neural Network that are used for computing disproportionality are described. Tree maps and other graphical techniques are used to display the disproportionality results. RESULTS: Spontaneously-reported adverse events in pharmacovigilance are collected from physicians, patients, or the medical literature by regulatory agencies, pharmaceutical companies and device manufacturers to monitor the safety of a product once it reaches the market. In order to identify potential safety-signals, disproportionality analysis methods compare the rate at which a particular event of interest co-occurs with a given drug with the rate this event occurs without the drug in the event database. Tree maps are employed to interactively display the adverse events for particular drugs and compare the adverse events among the drugs. CONCLUSIONS: Interactive graphical displays of disproportionality allow the analyst to quickly identify safety signals and perform additional follow-up analyses. Combining statistical methods with dynamically interactive graphics affords insights into the data inaccessible by traditional analysis methods.
引用
收藏
页码:314 / 320
页数:7
相关论文
共 50 条
  • [31] A disproportionality analysis of FDA adverse event reporting system events for misoprostol
    Yang, Li
    Xu, Wenting
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [32] Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database
    Yang, Chengcheng
    Zhao, Wanqi
    Chen, Huihui
    Yao, Yinhui
    Zhang, Jingmin
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [33] Characterization and Disproportionality Analysis of Spontaneously Reported Cases of Medication Errors to the U S-F D A Adverse Event Reporting System
    Mazhar, F.
    Carnovale, C.
    Gentili, M.
    Clementi, E.
    Radice, S.
    DRUG SAFETY, 2018, 41 (11) : 1135 - 1135
  • [34] Adverse Events Induced by Oral Contraceptives: A Review on Reported Cases to a National Pharmacovigilance Centre
    Javidnikou, N.
    Shalviri, G.
    DRUG SAFETY, 2011, 34 (10) : 1016 - 1017
  • [35] A Real-World Pharmacovigilance Analysis of Cardiac Adverse Events Associated with Newer Antibody-Drug Conjugates: A Disproportionality Analysis from FDA Adverse Event Reporting System Database
    Dilip, Deepika
    Sharma, Pritika
    Pawa, Arpita
    Wu, Ben
    Veasaw, Kassidy
    Drugge, Elizabeth
    Steinberg, Amir
    BLOOD, 2024, 144 : 7800 - 7801
  • [36] Spontaneously Reported Adverse Events Following Immunisation with Sputnik V Vaccine in Montenegro
    Vukicevic, V.
    Stankovic, M.
    Vujovic, S.
    DRUG SAFETY, 2021, 44 (12) : 1419 - 1420
  • [37] Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales
    Widschwendter, Christian G.
    Karayal, Onur N.
    Kolluri, Sheela
    Vanderburg, Douglas
    Kemmler, Georg
    Fleischhacker, W. Wolfgang
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (12): : 1 - 6
  • [38] Spontaneously reported adverse drug events related to tapentadol and oxycodone/naloxone in Australia
    Abeyaratne, Carmen
    Lalic, Samanta
    Bell, J. Simon
    Ilomaeki, Jenni
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2018, 9 (04) : 197 - 205
  • [39] PHARMACOVIGILANCE ANALYSIS OF FDA ADVERSE EVENTS REPORTING SYSTEM FOR MAVACAMTEN
    Matai, Pallavi
    Amirian, Aslan
    Khadka, Sulochana
    Gavilanes, Diana
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 560 - 560
  • [40] Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase)
    Akagi, Tomoaki
    Hamano, Hirofumi
    Miyamoto, Hirotaka
    Takeda, Tatsuaki
    Zamami, Yoshito
    Ohyama, Kaname
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 81 (01) : 129 - 137